Pilot PARTUM: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity - CIHR, INVENT and CanVECTOR funded with co-PIs @leslieskeith and @RodgerMarc
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial https://t.co/9zHeUIda7o
Great excitement this morning pressing the randomise button with @drjendonnelly! Looking forward to hopefully contributing to a change in postnatal #VTE prevention for all our Mums. Thanks to all our @PARTUMtrial/@RotundaHospital/@RCSI_Irl colleagues.
Learning about the @PARTUMtrial, with @DarineElChaarMD as the Ottawa site lead. Such an important study to determine if aspirin can safely prevent #postpartum VTE. Can this simple and cost-effective intervention change practice & save lives around the world? @leslieskeith
Stories like this help truly illustrate the importance of clinical research trials like the @PARTUMtrial (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) - proudly endorsed by @INVENT_VTE Council!
Learn more | Get involved: https://t.co/Ks1mHs20gA
@leslieskeith